每经记者｜杨建 每经编辑｜彭水萍 在11月18日举办的张江药谷国际创新大会·医疗器械论坛上，浦东新区相关负责人介绍，浦东已构建坚 实的医疗器械产业基础，创新成果持续涌现。截至目前，全区累计获批三类医疗器械注册证超1200张， 约占上海市40%；今年以来，又有5款创新医疗器械产品上市。另外，浦东已诞生多款首创产品，如全 球首创远程手术机器人（图迈）、全球首款分支型主动脉覆膜支架（Castor）、国内首款大局灶消融导 管等多款产品具备成为大品种的潜力。 NO.4 中国化学与物理电源行业协会：建立产能预警等机制，引导锂电行业"反内卷" 11月18日，《磷酸铁锂材料行业成本研究》研讨会在北京召开，中国化学与物理电源行业协会相关负责 人汤雁表示，当前锂电行业面临行业发展史上最严峻的"内卷"挑战，磷酸铁锂材料行业已成为锂电产业 链中竞争最激烈、利润承压最严重的环节。对此，汤雁代表行业协会提出三项行业协同行动倡议。 NO.5 全球首个ADC和核苷酸单体药物智造系统在沪发布 NO.2 千问APP国际版将在近期上线 面向海外市场的千问APP国际版将在近期上线。11月17日，阿里巴巴新推出的AI应用千问APP正式开启 公测，并计 ...

天眼查App显示，近日，上海江南宇盛医疗器械有限公司成立，法定代表人为张荣民，注册资本50万人 民币，经营范围为一般项目：第一类医疗器械销售；第一类医疗设备租赁；第二类医疗器械销售；第二 类医疗设备租赁；家具销售；办公用品销售；金属工具销售；卫生用品和一次性使用医疗用品销售；日 用百货销售；服装辅料销售；服装服饰批发；鞋帽零售；鞋帽批发；针纺织品及原料销售；电子元器件 零售；电子元器件批发；专用设备修理；办公设备销售；办公设备耗材销售；文具用品零售；文具用品 批发；通讯设备销售；通讯设备修理；化妆品零售；化妆品批发；家用电器销售；健康咨询服务（不含 诊疗服务）；技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广；信息咨询服务（不含 许可类信息咨询服务）；化工产品销售（不含许可类化工产品）；市场营销策划；企业形象策划；企业 管理咨询；货物进出口；技术进出口。（除依法须经批准的项目外，凭营业执照依法自主开展经营活 动）许可项目：第三类医疗器械经营。（依法须经批准的项目，经相关部门批准后方可开展经营活动， 具体经营项目以相关部门批准文件或许可证件为准）。 ...

Summary of Beta Bionics Conference Call Company Overview - **Company**: Beta Bionics (NasdaqGM: BBNX) - **Event**: 2025 Conference on November 18, 2025 Key Points Industry and Market Position - Beta Bionics is experiencing growth in both starts and revenue, with a focus on the insulin pump market [3][4] - The company is competing in a highly competitive environment, particularly against a tubeless pump competitor [7][27] Product Differentiation and Success Factors - The iLet insulin pump has a unique design and algorithm that differentiates it from competitors, leading to commercial success [3][4] - Pharmacy reimbursement has exceeded expectations, generating approximately $450 per month in recurring revenue and facilitating easier prescriptions for doctors [4][5] - The ease of use of the iLet pump is a significant selling point, making it easier for patients to start and maintain their treatment [8][9][12] Clinical Outcomes - The clinical outcomes of the iLet are reported to be as good or better than other systems on the market, with significant improvements in patient A1C levels [9][28] - The company emphasizes the importance of patient lifestyle improvements alongside clinical outcomes, which are often prioritized by users [13] Prescriber Profile and Market Strategy - Ideal prescribers for the iLet are open-minded doctors who prioritize patient outcomes and are willing to adopt new technologies [16][17] - The sales strategy is data-driven, focusing on demonstrating the product's effectiveness through real-time data access for healthcare providers [19] Market Share and Growth Projections - Beta Bionics estimates capturing approximately 11% of new patient starts in the U.S. market, with potential for growth as the sales force expands [23] - The company aims to increase its territories from 63 to around 120 in the long term, with ongoing investments in sales coverage [25] Future Product Development - Beta Bionics is working on a patch pump, targeting commercialization by the end of 2027, with ongoing manufacturing and regulatory preparations [33][40] - The patch pump will be pharmacy-only, leveraging existing pharmacy reimbursement agreements to facilitate market entry [45][47] Regulatory and Compliance Updates - The company is addressing a remediation effort for approximately 34,000 cases, expected to be completed by June 2026 [66] - Ongoing communication with the FDA is in place, with updates provided every 45 days regarding compliance matters [64][66] Conclusion - Beta Bionics is positioned for growth in the insulin pump market, with a focus on product differentiation, ease of use, and strong clinical outcomes. The company is actively preparing for future product launches while managing regulatory compliance effectively.

证券代码：688617 证券简称：惠泰医疗 公告编号：2025-051 深圳惠泰医疗器械股份有限公司 二、对公司的影响 上述医疗器械注册证的取得，有利于丰富公司的产品种类，扩充公司在外周领域的产品布局，不断满足 多元化的临床需求，进一步增强公司的核心竞争能力。 三、风险提示 上述产品后续实际销售情况取决于未来市场的推广效果，公司目前尚无法预测上述产品对公司未来营业 收入的影响，敬请广大投资者理性投资、注意投资风险。 特此公告。 深圳惠泰医疗器械股份有限公司董事会 关于自愿披露取得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 近日，深圳惠泰医疗器械股份有限公司（以下简称"公司"）全资子公司湖南埃普特医疗器械有限公司取 得一项医疗器械注册证，具体情况如下： 一、医疗器械注册证的具体情况 ■ 2025年11月19日 ...

截至2025年11月18日收盘，联影医疗(688271)报收于134.25元，上涨0.19%，换手率0.5%，成交量4.08万 手，成交额5.44亿元。 当日关注点 公司公告汇总 联影医疗持股5%以上股东宁波梅山保税港区影聚投资管理合伙企业（有限合伙）、宁波梅山保税港区 影力投资管理合伙企业（有限合伙）及其一致行动人于2025年9月1日至11月14日期间通过集中竞价方式 合计减持公司股份5,478,055股，占公司总股本的0.66%。本次权益变动后，上述股东合计持股比例由 6.62%下降至5.96%，权益变动触及1%刻度。本次减持为履行已披露的减持计划，不触及要约收购，不 会导致公司控股股东及实际控制人发生变化，对公司治理结构及持续经营无重大影响。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：11月18日主力资金净流出3508.96万元，占总成交额6.46%。 来自公司公告汇总：联影医疗持股5%以上股东及其一致行动人减持5,478,055股，持股比例由 6.62%降至5.96%，权益变动触及1%刻度。 交易信息 ...

本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 股东持有的基本情况 本次减持计划实施前，奕瑞电子科技集团股份有限公司（以下简称"公司""奕瑞科技"）股东天津红杉聚 业股权投资合伙企业（有限合伙）（以下简称"天津红杉"）、北京红杉信远股权投资中心（有限合伙） （以下简称"北京红杉"）分别持有公司股份11,785,883股和5,547,286股，分别占本次减持前公司总股本 的5.89%和2.77%。上述股份均为公司IPO前及上市后权益分派资本公积转增股本取得的股份，该部分股 份已于2021年9月22日、2023年4月24日、2024年6月17日、2025年6月19日上市流通。 ● 减持计划的实施结果情况 2025年7月24日，公司披露了《奕瑞科技关于公司股东减持股份计划的公告》（公告编号：2025- 049），公司股东天津红杉、北京红杉拟通过大宗交易的方式减持其所持有的公司股份合计不超过 4,004,367股，减持比例合计不超过本次减持前公司总股本的2%。截止目前，上述减持计划时间区间届 满。 近 ...

Enovis (NYSE:ENOV) 2025 Conference November 18, 2025 10:30 AM ET Company ParticipantsDamien McDonald - CEOBen Berry - CFOConference Call ParticipantsYoung Lee - MedTech AnalystYoung LeeAll right, great. Why don't we kick this session off? My name is Young Lee, one of the medtech analysts at Jefferies. Welcome, everyone. Really pleased to be joined by management from Enovis. To my right, you have Damien McDonald, the CEO, newly appointed CEO, been about half a year now. Then Ben Berry, CFO. In the crowd, we ...

Boston Scientific (BSX) closed the last trading session at $101.76, gaining 1.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $127.55 indicates a 25.3% upside potential.The mean estimate comprises 31 short-term price targets with a standard deviation of $6.38. While the lowest estimate of $113.00 indicates an 11.1% increase from the current price level, the most optimistic analy ...

For the quarter ended October 2025, Medtronic (MDT) reported revenue of $8.96 billion, up 6.6% over the same period last year. EPS came in at $1.36, compared to $1.26 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $8.86 billion, representing a surprise of +1.11%. The company delivered an EPS surprise of +3.82%, with the consensus EPS estimate being $1.31.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expe ...

Zynex (NasdaqGS:ZYXI) Q3 2025 Earnings Call November 18, 2025 09:00 AM ET Company ParticipantsStephen Dyson - CEOVikram Bajaj - CFOOperatorGood morning, ladies and gentlemen, and thank you for standing by. Welcome to the Zynex third quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. As a reminder, this conference is being recorded. I would now like to turn the conference over to Vikram Bajaj, Chief Financial Officer of Zynex. Please go ahead.Vikram BajajThank yo ...